DGN549-C
- Generic Name
- DGN549-C
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaMyeloproliferative NeoplasmMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyDrug: Granulocyte Colony-Stimulating FactorProcedure: Multigated Acquisition Scan
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06034470
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath